The Liver Diseases group is a referent at national and international level in research in liver diseases field. The prominent involvement in clinical trials is an indication of our professionals’ commitment with liver diseases patients as we are currently participating in 53 clinical trials, of which 12 were initiated in 2022. Another essential feature of the group is the active contribution of our members in some of the most significant societies of this field national and internationally (Executive and Scientific Committees of AEEH, Governing Board of EASL). Additionally, we collaborate in international consortiums and projects funded by European institutions such as EU-PEARL, LiverScreen, among others.

Group Leader
Joan Genescà Ferrer

Principal Investigator (PI)
Maria Buti Ferret, Isabel Campos Varela, Juan Ignacio Esteban Mur, Maria Martell Pérez-Alcalde, Beatriz Minguez Rosique, Juan Manuel Pericàs Pulido, Josep Quer Sivila, Maria Del Mar Riveiro Barciela, Macarena Simon-Talero Horga, Victor Manuel Vargas Blasco, Meritxell Ventura Cots

Researchers
Lluis Castells Fusté, Immaculada Raurell Saborit, David Tabernero Caellas, Mònica Pons Delgado, Jordi Llaneras Artigues, Adriana Palom Agusti, Monica Higuera Urbano

PhD Students
María Bermúdez Ramos, Meritxell Llorens Revull, Joan Martínez Campreciós, Elena Vargas Accarino, Judit Vidal Gonzalez, Ares Aurora Villagrasa Vilella, César Jiménez Hernández, Maria Luisa Roade Tato, Marta Ibañez Lligoña, Maria Martínez Gómez, Ana Barreira, Cristina Marcos, Sergi Colomer Castell, Carolina Campos Martinez, Juan Carlos Ruiz Cobo, Ana Feliu, Jesus Manuel Rivera, Aurora Barberá Bellés, Mar Gil Soler, Ramiro Manzano

Lab Technicians
Damir Garcia Cehic

Nursing and Technical Staff
Susana Anton Calvo, Cristina Adame Castillo, Elena de Sena Fernández, Emma Bigas, Ester Palacio Gutierrez, Marcella Salzano, Maria Margarita Torrens Buscató, Judit Vico Romero, Laura Puente Ramo, Claudia Ana Burillo, Laura Cecconi, Montserrat Gómez

105

PUBLICATIONS

57.1%

%Q1

1,281

IMPACT FACTOR

12.20

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Campos-Varela I, Price JC, Dodge JL, Terrault NA
Transplantation, HIV Serostatus and Registry Data, Room for Improvement.
Am J Transplant. 2022 Sep;22(9):2283-2284
DOI: doi: 10.1111/ajt.17062
IF: 9.37

Riveiro-Barciela M, Barreira-Diaz A, Callejo-Perez A, Munoz-Couselo E, Diaz-Mejia N, Diaz-Gonzalez A, Londono MC, Salcedo MT, Buti M
Retreatment with Checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study.
Clin Gastroenterol Hepatol. 2022 Apr 26:S1542-3565(22)00403-7
DOI: doi: 10.1016/j.cgh.2022.03.050
IF: 13.58

Buti M
Hepatitis D virus: more attention needed
Nat Rev Gastroenterol Hepatol. 2022 Sep;19(9):556
DOI: doi: 10.1038/s41575-022-00664-0
IF: 73.08

Ventura-Cots M, Bataller R, Lazarus JV, Benach J, Pericas JM
Applying an equity lens to liver health and research in Europe.
J Hepatol. 2022 Dec;77(6):1699-1710.
DOI: doi: 10.1016/j.jhep.2022.07.021.
IF: 30.08

Buti M, Craxi A, Foster GR, Maticic M, Negro F, Zeuzem S, Zoulim F
Viral hepatitis elimination: Towards a hepatitis-free world.
J Hepatol. 2022 Nov;77(5):1444-1447.
DOI: doi: 10.1016/j.jhep.2022.06.034.
IF: 30.08

Aislamiento y caracterización molecular de Células Tumorales Circulantes (CTCs): potenciales biomarcadores en Carcinoma Hepatocelular
Principal Investigator: Beatriz Minguez Rosique
Agency: Instituto de Salud Carlos III
Funding: 183,920€
Period: 2022-2024

Impact of HLA haplotypes and HDV viremia in developing of clinical events and quality of life of patients with chronic hepatitis delta
Principal Investigator: Maria Buti Ferret
Agency: Instituto de Salud Carlos III
Funding: 117,370€
Period: 2021-2023

EU Patient- cEntric clinicAl tRial pLatform – EU PEARL
Principal Investigator: Joan Genescà Ferrer
Agency: The Innovative Medicines Initiative
Funding: 1,987,375€
Period: 2019-2023

Biodegradable nanoparticles of Simvastatin as new therapeutic tool for chronic liver diseases (NANOSIM)
Principal Investigator: Joan Genescà Ferrer
Agency: Instituto de Salud Carlos III
Funding: 199,946,45€
Period: 2019-2022

PRIMERS AND METHODS FOR DETECTING HUMAN HEPATITIS C VIRUS (HCV) VARIANTS IN AN ISOLATED SAMPLE
Priority Number: EP14736385.7
Priority Date: 18/04/2018
Applicants: 37.5% CIBERehd / 37.5% VHIR / 25% Roche

eCOREs